Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A12A5F | ISIN: CA31447P1009 | Ticker-Symbol: RV41
Frankfurt
28.03.24
08:20 Uhr
10,200 Euro
+0,500
+5,15 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
FENNEC PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
FENNEC PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
10,20010,40028.03.
10,10010,40028.03.

Aktuelle News zur FENNEC PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DiFennec Pharmaceuticals CFO sells $153k in company stock1
21.03.FENNEC PHARMACEUTICALS INC. - 8-K, Current Report1
21.03.Fennec Pharmaceuticals GAAP EPS of -$0.10 misses by $0.081
21.03.Fennec Pharmaceuticals Inc: Fennec loses $16.04-million (U.S.) in 20231
21.03.Fennec Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary1
21.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Full Year and Fourth Quarter 2023 Financial Results and Provides Business Update134~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize...
► Artikel lesen
20.03.Fennec Pharmaceuticals' Earnings Outlook2
20.03.Fennec Pharmaceuticals and Norgine to commercialize PEDMARQSI in Europe, Australia, and New Zealand1
19.03.Fennec exceeded Craig-Hallum's expectations with Norgine deal, stock PT raised1
19.03.Fennec (FENC) Signs Licensing Deal With Norgine, Stock Up1
19.03.Fennec Pharmaceuticals Inc: Fennec to release fiscal 2023 results March 211
19.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals to Report Full Year and Fourth Quarter 2023 Financial Results on March 21, 20242
18.03.Norgine secures Pedmarqsi licence from Fennec in deal worth up to $272m1
18.03.Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand159Agreement pairs Norgine's commercial expertise and leading European footprint with PEDMARQSI, the first and only approved therapy in the European Union and U.K. for reducing the risk of cisplatin-induced...
► Artikel lesen
18.03.Fennec Pharmaceuticals Inc: Fennec enters Pedmarqsi licensing deal with Norgine2
18.03.Fennec, Norgine Reach Licensing Deal To Commercialize Pedmarqsi In Europe, Australia, & New Zealand2
18.03.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand4
29.02.Fennec Pharmaceuticals Inc: Fennec expects revenue of $20.7M to $21.2M for 20232
29.02.Fennec Pharmaceuticals reports Preliminary Unaudited Q4 results1
29.02.Fennec Pharmaceuticals Inc.: Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results135~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~ ~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~ RESEARCH TRIANGLE...
► Artikel lesen
Seite:  Weiter >>
39 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1